Effect of DNA Repair Deficiencies on the Cytotoxicity of Drugs Used in Cancer Therapy – A Review

ISSN: 1875-533X (Online)
ISSN: 0929-8673 (Print)


Volume 21, 38 Issues, 2014


Download PDF Flyer




Current Medicinal Chemistry

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 5th of 59 in Chemistry & Medicinal
  • 41st of 261 in Pharmacology & Pharmacy
  • 80th of 290 in Biochemistry & Molecular Biology

Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Atta-ur-Rahman, FRS
Honorary Life Fellow
Kings College
University of Cambridge
Cambridge
UK
Email: cmc@benthamscience.org

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 4.07
5 - Year: 4.471

Effect of DNA Repair Deficiencies on the Cytotoxicity of Drugs Used in Cancer Therapy – A Review

Author(s): Jose Manuel Calderón-Montaño, Estefanía Burgos-Morón, Manuel Luis Orta and Miguel Lopez-Lazaro

Affiliation: Department of Pharmacology, Faculty of Pharmacy, University of Seville, Spain. C/ Profesor Garcia Gonzalez, 41012, Sevilla, Spain

Abstract

Tumor cells often have defects in DNA repair pathways that make them vulnerable to specific DNA-damaging anticancer agents. The identification of DNA repair defects in tumor cells and the evaluation of their influence on the cytotoxicity of anticancer drugs are active areas of scientific investigation that may help rationalize and improve cancer chemotherapy. This article reviews the available data on the influence of defects in proteins involved in the major DNA repair pathways (i.e., homologous recombination, non-homologous end joining, base excision repair, nucleotide excision repair, mismatch repair, Fanconi anemia repair, translesion synthesis and direct reversal repair) on the cytotoxicity of the FDA-approved anticancer drugs. It is shown that specific deficiencies in these DNA repair pathways alter the cytotoxicity of 60 anticancer drugs, including classical DNA-targeting drugs (e.g., alkylating agents, cytotoxic antibiotics, DNA topoisomerase inhibitors and antimetabolites) and other drugs whose primary pharmacological target is not the DNA (e.g., antimitotic agents, hormonal and targeted therapies). This information may help predict response to anticancer drugs in patients with tumors having specific DNA repair defects

Keywords: Anticancer, chemotherapy, DNA damage, DNA damage response

Purchase Online Rights and Permissions

Article Details

Volume: 21
First Page: 1
Last Page: 37
Page Count: 37
DOI: 10.2174/0929867321666140601203816
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science